A synthetic biosimilar savings model shows why availability alone may not lower spending when substitution, formulary placement, rebates, inventory, prescriber trust, and patient cost share are unresolved.

A synthetic influence-style infusion model compares site-of-care decisions across safety, treatment completion, avoidable cost, patient burden, and payer policy.

A synthetic plan-year model shows how approval timing, eligible population, price tier, stop-loss readiness, rebates, provider capacity, and access friction can combine into budget shock.

A synthetic Marketplace integrity model separates improper enrollment risk from consumer confusion, subsidy exposure, notices, agent oversight, and coverage disruption.

Anti-fraud actions can protect public dollars and still create access pressure when review capacity, payment holds, provider supply, and beneficiary complexity collide.

A synthetic credentialing model shows why a clinician can be clinically acceptable and still miss a start date because approvals, documents, EHR access, orientation, and payer enrollment move on different clocks.

Electronic prior authorization can reduce some delays, but the API only helps when criteria, data, attachments, workflow, and payer readiness line up.

A synthetic specialty-drug first-fill model separates coverage, documentation, pharmacy access, affordability, and patient-reachability delays.

A crowded emergency department delay can look like a staffing problem, a demand surge, a diagnostic bottleneck, or a boarding problem. A small synthetic BBN separates those explanations.

A tennis serve is practiced as a repeatable motion, but match pressure changes toss variability, fatigue, target risk, and contact point. A causal detective story separates those suspects.